Enveric Biosciences shares rose after the company said it received US Patent No. 12,492,179, extending protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules being developed to treat neuropsychiatric conditions. Despite the news, Stocktwits sentiment around the stock remained bearish.